Blood pH and COVID-19
- PMID: 36690587
- DOI: 10.1002/ardp.202200558
Blood pH and COVID-19
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is a worldwide war. Raising the blood pH might be a crucial strategy to chase COVID-19. The human blood is slightly alkaline, which is essential for cell metabolism, normal physiology, and balanced immunity since all of these biological processes are pH-dependent. Varieties of physiologic derangements occur when the blood pH is disrupted. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) proliferates in acidic blood that magnifies the severity of COVID-19. On the other side, blood acidemia is linked to increased morbidity and mortality because of its complications on immunity, especially in the elderly and in critical diseases such as cancer, musculoskeletal degradation, renal, cardiac, and pulmonary disorders, which result in many pathological disorders such as osteomalacia, and disturbing the hematopoiesis. Additionally, acidemia of the blood facilitates viral infection and progression. Thus, correcting the acid-base balance might be a crucial strategy for the treatment of COVID-19, which might be attributed to the distraction of the viral spike protein to its cognate receptor angiotensin-converting enzyme 2 and supporting the over-taxed immunity.
Keywords: COVID-19; SARS-CoV-2; acidemia; bicarbonate; blood pH; immunity.
© 2023 Deutsche Pharmazeutische Gesellschaft.
Similar articles
-
SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.Elife. 2020 May 26;9:e58603. doi: 10.7554/eLife.58603. Elife. 2020. PMID: 32452762 Free PMC article.
-
Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.PLoS One. 2022 Jul 13;17(7):e0271112. doi: 10.1371/journal.pone.0271112. eCollection 2022. PLoS One. 2022. PMID: 35830431 Free PMC article.
-
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20. mBio. 2020. PMID: 32913009 Free PMC article.
-
Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?Front Endocrinol (Lausanne). 2021 Oct 22;12:725967. doi: 10.3389/fendo.2021.725967. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34745001 Free PMC article. Review.
-
COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?J Intern Med. 2020 Oct;288(4):410-421. doi: 10.1111/joim.13101. Epub 2020 Jun 8. J Intern Med. 2020. PMID: 32459372 Free PMC article. Review.
References
REFERENCES
-
- P. K. Hamilton, N. A. Morgan, G. M. Connolly, A. P. Maxwell, Ulster Med. J. 2017, 86, 161.
-
- L. L. Hamm, N. Nakhoul, K. S. Hering-Smith, Clin. J. Am. Soc. Nephrol. 2015, 10, 2232.
-
- X. Li, X. Ma, Crit. Care 2020, 24, 198.
-
- R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, N. Zhu, Y. Bi, X. Ma, F. Zhan, L. Wang, T. Hu, H. Zhou, Z. Hu, W. Zhou, L. Zhao, J. Chen, Y. Meng, J. Wang, Y. Lin, J. Yuan, Z. Xie, J. Ma, W. J. Liu, D. Wang, W. Xu, E. C. Holmes, G. F. Gao, G. Wu, W. Chen, W. Shi, W. Tan, Lancet 2020, 395, 565.
-
- J. Shang, Y. Wan, C. Luo, G. Ye, Q. Geng, A. Auerbach, F. Li, Proc. Natl. Acad. Sci. USA 2020, 117, 11727.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous